Skip to main content

Table 2 Adverse events observed in patients administered adjuvant chemotherapy with DCS

From: Phase II feasibility study of adjuvant chemotherapy with docetaxel/cisplatin/S-1 followed by S-1 for stage III gastric cancer

Toxicity No. of patients (%)
Grade 3 or higher All
Hematological toxicity
 Neutropenia 3 (10.0) 14 (46.7)
 Leukopenia 3 (10.0) 12 (40.0)
 Anemia 2 (6.7) 10 (33.3)
 Thrombocytopenia 0 (0.0) 8 (26.7)
 Febrile neutropenia 4 (13.3) 4 (13.3)
Non-hematological toxicity
 Nausea 1 (3.3) 19 (63.3)
 Diarrhea 1 (3.3) 6 (20.0)
 Anorexia 4 (13.3) 22 (73.3)
 Fatigue 3 (10.0) 23 (76.7)
 Stomatitis 0 (0.0) 5 (16.7)
 Abdominal distension 0 (0.0) 2 (6.7)
 Alopecia 0 (0.0) 17 (56.7)
 Dry skin 0 (0.0) 2 (6.7)
 Dysgeusia 0 (0.0) 3 (10.0)
 Skin pigmentation 0 (0.0) 4 (13.3)